JOHN KIRKWOOD to Interferons
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Interferons.
Connection Strength
2.484
-
Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol. 2011 Jul; 33(4):385-91.
Score: 0.344
-
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med. 2010 Nov 03; 8:108.
Score: 0.338
-
Predictors of response to interferon therapy. Curr Opin Oncol. 2009 Mar; 21(2):138-43.
Score: 0.301
-
Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med. 2008 Oct 27; 6:62.
Score: 0.294
-
Interferons in the treatment of solid tumors. Cancer Treat Res. 2005; 126:207-41.
Score: 0.226
-
Survival benefit in melanoma. J Clin Oncol. 1998 Jan; 16(1):388-9.
Score: 0.139
-
Interferons in melanoma. Curr Opin Oncol. 1996 Mar; 8(2):167-74.
Score: 0.122
-
Interferons in the therapy of solid tumors. Oncology. 1994 Mar-Apr; 51(2):129-36.
Score: 0.106
-
A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon. PLoS One. 2014; 9(1):e86375.
Score: 0.106
-
The role of interferons in the therapy of melanoma. Immunol Ser. 1994; 61:239-50.
Score: 0.105
-
Adjuvant therapy for melanoma. Cancer J. 2012 Mar-Apr; 18(2):192-202.
Score: 0.093
-
Role of interferons in the therapy of melanoma. J Invest Dermatol. 1990 Dec; 95(6 Suppl):180S-184S.
Score: 0.085
-
Melanoma: therapeutic options with recombinant interferons. Semin Oncol. 1985 Dec; 12(4 Suppl 5):7-12.
Score: 0.060
-
Adjuvant therapy of melanoma. Semin Cutan Med Surg. 2003 Mar; 22(1):55-67.
Score: 0.050
-
An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. Cancer Cell. 2019 01 14; 35(1):33-45.e6.
Score: 0.037
-
Adjuvant therapy of melanoma. Semin Surg Oncol. 1998 Jun; 14(4):302-10.
Score: 0.036
-
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol. 2014 Nov 20; 32(33):3771-8.
Score: 0.028
-
Cytokine-based therapy for melanoma: pre-clinical studies. Forum (Genova). 2000 Jul-Sep; 10(3):204-26.
Score: 0.010
-
Glioblastoma multiforme: pathology, natural history and treatment. Cancer Treat Rev. 1984 Mar; 11(1):1-26.
Score: 0.003